EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCC

Kazunari Tanaka iD, Kunihiko Tsuji iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Masashi Hirooka iD, Kazuya Kariyama iD, Joji Tani iD, Masanori Atsukawa iD, Koichi Takaguchi iD, Ei Itobayashi iD, Takashi Nishimura iD, Toru Ishikawa iD und 45 weitere

Liver International · 2026

DOI: 10.1111/liv.70803 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Kazunari Tanaka und 56 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Protein Precursors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims For unresectable hepatocellular carcinoma (HCC), atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) are widely used first‐line immunotherapies; however, biomarkers to guide regimen selection before treatment initiation remain undefined. We investigated whether baseline des‐γ‐carboxy prothrombin (DCP) modifies objective response rate (ORR) according to treatment regimen.

Methods

We analysed 1464 patients with unresectable HCC treated with first‐line systemic therapy between 2020 and 2025 across multiple centers. Patients were divided into training and validation cohorts. Restricted cubic spline‐based interaction models were used to evaluate the association between baseline DCP and ORR according to treatment regimen. The predicted absolute difference in ORR (ΔORR) between regimens was examined across continuous DCP values, with a prespecified 10% threshold considered clinically meaningful. Robustness was assessed using leave‐one‐center‐out and repeated random‐split sensitivity analyses.

Results

Overall ORR did not differ significantly between Atez/Bev and Dur/Tre. However, a significant interaction between baseline DCP and treatment regimen was observed in both cohorts. Atez/Bev showed a relatively stable ORR across DCP concentrations, whereas Dur/Tre showed a DCP‐dependent increase in ORR. At low DCP levels, Atez/Bev was favoured; with increasing DCP levels, the relative benefit shifted toward Dur/Tre. Sensitivity analyses confirmed a consistent DCP‐dependent transition pattern, although the DCP level at which ΔORR exceeded 10% varied across analyses, supporting a transition zone rather than a fixed cutoff.

Conclusions

Baseline DCP may modify the relative treatment benefit between Atez/Bev and Dur/Tre in unresectable HCC. Rather than defining a rigid cutoff, DCP appears to delineate a continuum in which higher levels increasingly favour Dur/Tre, providing a practical framework for individualized immunotherapy selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedProtein PrecursorsBevacizumabAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansProthrombinFemaleMaleAgedTreatment OutcomeRetrospective StudiesBiomarkers

Stichwörter der Autor:innen

des‐γ‐carboxy prothrombinhepatocellular carcinomainteractionobjective response rate

Substanzen

acarboxyprothrombinAntibodies, Monoclonal, HumanizedProthrombinProtein PrecursorsatezolizumabBevacizumabtremelimumabAntibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

ORCID-Profile: Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Taeang Arai, Akemi Tsutsui, Fujimasa Tada, Hideko Ohama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takanori Matsuura, Soo Ki Kim, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Zitieren

APA

Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., …, & Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group (2026). Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCC. Liver International. https://doi.org/10.1111/liv.70803

Vancouver

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCC. Liver International. 2026. doi:10.1111/liv.70803

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Kazunari and Tsuji, Kunihiko and Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Matono, Tomomitsu and Ueda, Yoshihide and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Okamura, Jumpei and Tamai, Hideyuki and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Tada, Fujimasa and Ohama, Hideko and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Komatsu, Shohei and Fukumoto, Takumi and Matsuura, Takanori and Kim, Soo Ki and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group, Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group},
  title = {Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCC},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70803}
}
Kostenlos starten →